“You can harm someone at whatever pace you want, but you're still harming them,”...
Underrepresentation of population subgroups in clinical research is bad for the ...
M&A activity for pharma CMOs reached a peak in 2021, with 2022 seeing a slight d...
Rinvoq is expected to have a rapid uptake in the CD market by healthcare provide...
VANFLYTA was first approved as a monotherapy in the relapsed/refractory setting.
The NDA included data from the Phase III FRESCO-2 and FRESCO trials conducted in...
A few weeks after Covid-19 emergency declaration ended, the FDA has approved Pax...
The immune-oncology market is forecasted to grow to over $150 billion by 2028, b...
The larger facility is expected to help Touchlight supply plasmid DNA to meet th...
Insulin delivery devices are proliferating despite equitable insulin access bein...
As US drug prices increase, consumers are turning to illegal online pharmacies t...
Patients with DEB have extremely fragile skin that blisters and tears with minor...
The U.K. government on Thursday unveiled an $800 million package to bolster the ...
In a new study, a medicine from Bristol Myers Squibb nearly doubled the treatmen...
“We’ve lost an opportunity to have direct government purchases of hundreds of th...
Can AI diagnose a disease? Are Wegovy's days numbered? And what makes AI halluci...
